Everything below concerns HGF mimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
=== Pharmacokinetics === The time that it takes for serum concentrations of clinafloxacin to reach the maximum concentration (Cmax) in healthy volunteers after taking a dose by mouth is 0.7 hours. The elimination half-life in humans is 6.1 hours. Steady state levels of clinafloxacin are achieved in 3 days of twice daily dosing by mouth in healthy volunteers. About half of an administered clinafloxacin dose is found unchanged in the urine, meaning that the drug is cleared from the blood stream roughly equally by hepatic metabolism (liver-induced degradation) and renal elimination (kidney-mediated removal).
== Naturally occurring nuclides that are not primordial == Some unstable isotopes which occur naturally (such as 14C, 3H, and 239Pu) are not primordial, as they must be constantly regenerated. This occurs by cosmic radiation (in the case of cosmogenic nuclides such as 14C and 3H), or (rarely) by such processes as geonuclear transmutation (neutron capture by uranium in the case of 237Np and 239Pu). Other examples of common naturally occurring but non-primordial nuclides are isotopes of radon, polonium, and radium, which are all radiogenic daughters of uranium decay and are found in uranium ores. The stable argon isotope 40Ar is actually more common as a radiogenic nuclide than as a primordial nuclide, forming almost 1% of the Earth's atmosphere, which is generated by the electron capture decay of the extremely long-lived radioactive primordial isotope 40K, whose half-life is on the order of a billion years and thus has been generating argon since early in the Earth's existence. (Primordial argon was dominated by the alpha process nuclide 36Ar, which is significantly rarer than 40Ar on Earth.) And the classical decay chains of radiogenic elements derive from the long-lived radioactive primordial nuclides 232Th, 235U, and 238U. These nuclides are described as geogenic, meaning that they are decay or fission products of uranium or other actinides in subsurface rocks. All such nuclides have shorter half-lives than their parent radioactive primordial nuclides.
Deep learning uses several layers of neurons between the network's inputs and outputs. The multiple layers can progressively extract higher-level features from the raw input. For example, in image processing, lower layers may identify edges, while higher layers may identify the concepts relevant to a human such as digits, letters, or faces. Deep learning has been used to improve the performance of programs in subfields of artificial intelligence including computer vision, speech recognition, natural language processing, image classification and others. Deep neural networks and backpropagation had been in development since 1950. Starting in 2012, the speed of deep learning was increased one hundred-fold by switching to GPUs, and there were enormous amounts of data available on the internet (called at the time "big data") as well as curated datasets used for benchmark testing, such as ImageNet. Usage of deep learning increased in 2012–2015 due to these improvements. In 2025, Geoffrey Hinton said that, until the 2010s, "We couldn't do anything very impressive because we didn’t have enough data and we didn't have enough computation."
As the tepid reaction to the German Anschluss with Austria had shown, the governments of France, the United Kingdom and Czechoslovakia were set on avoiding war at any cost. The French government did not wish to face Germany alone and took its lead from the British government, led by Prime Minister Neville Chamberlain. He contended that Sudeten German grievances were justified and believed that Hitler's intentions were limited. That made Britain and France advise Czechoslovakia to concede to the German demands. Beneš resisted, and on 20 May 1938, a partial mobilisation was under way in response to the possible German invasion. It is suggested that the mobilisation could have been launched on basis of Soviet misinformation about Germany being on verge of invasion, which aimed to trigger war in Western Europe. On 30 May, Hitler signed a secret directive for war against Czechoslovakia to begin no later than 1 October. In the meantime, the British government demanded for Beneš to request a mediator. Not wishing to sever his government's ties with Western Europe, Beneš reluctantly accepted. The British appointed Lord Runciman and instructed him to persuade Beneš to agree to a plan acceptable to the Sudeten Germans. On 2 September, Beneš submitted the Fourth Plan, which granted nearly all of the demands of the Karlsbader Programm. Intent on obstructing conciliation, however, the SdP held demonstrations that provoked the police in Ostrava on 7 September. The Sudeten Germans broke off negotiations on 13 September, and violence and disruption ensued.
Sources: en.wikipedia.org
=== Indigenous rights === Findlay has also made opposition to Indigenous rights, including the repeal of DRIPA, core to her platform while campaigning for leadership of the BC Conservative Party. She accused leadership rival Peter Milobar of having a conflict of interest in how he handled opposition to the legislation because his wife and other family members were Indigenous, which led to accusations of racism. In her acceptance speech as leader, she doubled down, stressing “The NDP’s radical ideology has devastated property rights, backroom-signed treaties, and the NDP’s economic vandalism has to end.” Findlay and her staff were also alleged to have issued guidance to several caucus members and their staffers that they were to use the terms Indigenous, Aboriginal or Indian instead of First Nations. Her office was said to have cited the federal Indian Act as justification for using this term. When questioned by Black Press, she denied the allegations, claiming “It’s simply not true. There was no directive, nothing like that.”
Other species of ants can form chains to bridge gaps over water, underground, or through spaces in vegetation. Some species also form floating rafts that help them survive floods. These rafts may also have a role in allowing ants to colonise islands. Polyrhachis sokolova, a species of ant found in Australian mangrove swamps, can swim and live in underwater nests. Since they lack gills, they go to trapped pockets of air in the submerged nests to breathe.
In 1867, the Austro-Hungarian compromise and the introduction of the dual monarchy left the Czechs and their aristocracy without the recognition of separate Bohemian state rights for which they had hoped. Bohemia remained part of the Austrian Crown Lands. In Bohemia, opposition to dualism took the form of isolated street demonstrations, resolutions from district representations, and even open air mass protest meetings, confined to the biggest cities, such as Prague. The Czech newspaper Národní listy complained that the Czechs had not yet been compensated for their wartime losses and sufferings during the Austro-Prussian War, and had just seen their historic state rights tossed aside and their land subsumed into the "other" half of the Austro-Hungarian Monarchy, commonly called "Cisleithania". The Czech hopes were revived again in 1870–1871. In an Imperial Rescript of 26 September 1870, Franz Joseph referred again to the prestige and glory of the Bohemian Crown and to his intention to hold a coronation. Under Minister-President Karl Hohenwart in 1871, the government of Cisleithania negotiated a series of fundamental articles spelling out the relationship of the Bohemian Crown to the rest of the Habsburg Monarchy. On 12 September 1871, Franz Joseph announced:
Most syndrome types revolved around menstruation, or lack thereof. The patient was entrusted with recording not only the frequency, but also the "volume, color, consistency, and odor of menstrual flow." This placed responsibility of symptom recording on the patient, and was compounded by the earlier discussed issue of female chastity and honor. This meant that diagnosing female infertility was difficult, because the only symptoms that were recorded and monitored by the physician were the pulse and color of the tongue.
Subjects in Byzantine art were primarily Christian and typically non-naturalistic in their representation. Emerging from both the earliest Christian and Late Antique art, many early examples were lost amid the Roman Persecutions; the fragmented mosaics of the 3rd-century Dura-Europos church are a unique exception. Such Byzantine mosaics, known for their gold ground style, became a hallmark of the empire, displaying both secular and sacred themes in diverse places, including churches (Basilica of San Vitale), the circus (Hippodrome of Constantinople), and the Great Palace of Constantinople. The early 6th-century reign of Justinian I saw systemic developments: religious art came to dominate, and once-popular public marble and bronze monumental sculpture fell out of favour due to pagan associations. Justinian commissioned the monumental Hagia Sophia church, and its influential elements became architectural hallmarks for the empire: the immense size, large dome, innovative use of pendentives and highly decorative interior were imitated as far north as the Cathedral of Saint Sophia in Novgorod and the Saint Sophia Cathedral in Kiev. The Hagia Sophia's creators, the engineer-architects Isidore of Miletus and Anthemius of Tralles, are uniquely esteemed; most Byzantine artists were unrecorded and typically deemed to have little importance.
Sources: en.wikipedia.org
=== Interpretation === Accurate interpretation takes a variety of factors into account, such as the thyroid hormones i.e. thyroxine (T4) and triiodothyronine (T3), current medical status (such as pregnancy), certain medications like propylthiouracil, temporal effects including circadian rhythm and hysteresis, and other past medical history.
=== Obstetrics === Fentanyl is sometimes given intrathecally as part of spinal anesthesia or epidurally for epidural anesthesia and analgesia. Because of fentanyl's high lipid solubility, its effects are more localized than morphine, and some clinicians prefer to use morphine to get a wider spread of analgesia. It is widely used in obstetrical anesthesia because of its short time to action peak (about 5 minutes), the rapid termination of its effect after a single dose, and the occurrence of relative cardiovascular stability. In obstetrics, the dose must be closely regulated to prevent large amounts of transfer from mother to fetus. At high doses, the drug may act on the fetus to cause neonatal withdrawal. For this reason, shorter-acting agents such as alfentanil or remifentanil may be more suitable in the context of inducing general anesthesia.
is rather small, in the convenience of comparison between difference samples, the notation is define as a ratio minus 1 and expressed in permil (‰). The Δ notation is inherited from traditional δ notation. But the reference is not a physical reference material. Instead, the reference frame is defined as the stochastic distribution of isotopologues in the sample. It means the values of Δ are to denote the excess or deficit of the isotopologue relative to the amount expected if a material conforms to the stochastic distribution. The calculation of stochastic distribution of methane isotopologues:
A 1995 study found that daily consumption of water treated with 4 tablets containing tetraglycine hydroperiodide reduced the uptake of radioactive iodine in human subjects to a mean of 1.1 percent, from a baseline mean of 16 percent, after a week of treatment. At 90 days of daily treatment, uptake was further reduced to a mean of 0.5 percent. However, unlike KI, tetraglycine hydroperiodide is not recommended by the WHO for this purpose. Iodine should be allowed at least 30 minutes to kill Giardia.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.